BCTXZ

BriaCell Therapeutics Corp. Series Z Warrants entitle holders to purchase shares of BriaCell Therapeutics common stock at a specified exercise price within a designated time frame. These warrants were issued as part of capital raising activities and provide an additional equity-linked instrument that trades separately from the underlying common stock. Series Z warrants offer investors leveraged exposure to potential increases in BriaCell's stock price, with returns amplified relative to movements in the common shares. Like other warrant series, Series Z warrants derive their value from both intrinsic value (the extent to which the stock price exceeds the exercise price) and time value (reflecting the remaining exercise period and stock volatility). When BriaCell's stock trades above the warrant's strike price, holders can exercise to purchase shares at the favorable exercise price or sell the warrants in the secondary market at a profit. The leverage characteristic of warrants means they can deliver outsized percentage gains during periods when the stock appreciates significantly. BriaCell Therapeutics is advancing targeted immunotherapy candidates for advanced breast cancer and other solid tumors through clinical development. The company's lead program, Bria-IMT, is being evaluated in clinical trials as both monotherapy and in combination with other cancer treatments. Success in clinical trials, regulatory milestones, partnership announcements, or other positive developments could catalyze stock price appreciation, creating value for warrant holders. These instruments are appropriate for investors with higher risk tolerance who believe BriaCell's clinical programs will succeed and drive substantial stock price growth. If the stock remains below the exercise price at expiration, the warrants become worthless.